In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...
Live Science on MSNOpinion
One molecule could usher revolutionary medicines for cancer, diabetes and genetic disease — but the US is turning its back on it
The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...
A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels ...
Jennifer Doudna is a Nobel laureate in chemistry and professor of biochemistry, biophysics and structural biology at the University of California, Berkeley. She has been a pioneer in CRISPR gene ...
When six infants around the world were diagnosed with an odd trio of symptoms (diabetes, epilepsy, and abnormally small heads ...
While most of the attention on CRISPR Therapeutics centers on the company’s Vertex-partnered cell therapy and looming FDA advisory committee meeting, Alex Harding, M.D., is cooking up the biotech's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback